Sparsentan approved to treat adult patients with primary immunoglobulin A nephropathy (IgAN)

Monday, 18 November 2024 17:18

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sparsentan (Filspari) to treat primary immunoglobulin A nephropathy (IgAN). IgA neuropathy, also known as Berger's disease, is a kidney disease that occurs when an antibody called immunoglobulin A (IgA) builds up in your kidneys. Sparsentan was approved under the International Recognition Procedure (IRP), following route B. The active ingredient in Filspari, sparsentan, works by...Request free trial